Rischin D - Search Results

1

Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors.

Holden SN, Eckhardt SG, Basser R, de Boer R, Rischin D, Green M, Rosenthal MA, Wheeler C, Barge A, Hurwitz HI. Holden SN, et al. Among authors: rischin d. Ann Oncol. 2005 Aug;16(8):1391-7. doi: 10.1093/annonc/mdi247. Epub 2005 May 19. Ann Oncol. 2005. PMID: 15905307 Free article. Clinical Trial.

2

Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.

Prince HM, Millward MJ, Rischin D, Blakey D, Francis P, Gates P, Chapple P, Quinn M, Juneja S, Wolf M, Januszewicz EH, Seymour JF, Brettell M, Strickland A, Zalcberg J, Richardson G, Scarlett J, Briggs P, Toner GC. Prince HM, et al. Among authors: rischin d. Ann Oncol. 1999 Apr;10(4):479-81. doi: 10.1023/a:1008317205955. Ann Oncol. 1999. PMID: 10370794 Free article. Clinical Trial.

3

Open label, multi-centre phase II study of raltitrexed ('Tomudex') in patients with inoperable squamous-cell carcinoma of head and neck.

Clarke SJ, Zalcberg J, Olver I, Mitchell PL, Rischin D, Dalley D, Green M, Davidson YE. Clarke SJ, et al. Among authors: rischin d. Ann Oncol. 2000 Feb;11(2):239-41. doi: 10.1023/a:1008369629944. Ann Oncol. 2000. PMID: 10761765 Free article. Clinical Trial.

4

A phase I trial of docetaxel and gemcitabine in patients with advanced cancer.

Rischin D, Boyer M, Smith J, Millward M, Michael M, Bishop J, Zalcberg J, Davison J, Emmett E, McClure B. Rischin D, et al. Ann Oncol. 2000 Apr;11(4):421-6. doi: 10.1023/a:1008384326701. Ann Oncol. 2000. PMID: 10847460 Free article. Clinical Trial.

5

Treatment with the novel anti-angiogenic agent PI-88 is associated with immune-mediated thrombocytopenia.

Rosenthal MA, Rischin D, McArthur G, Ribbons K, Chong B, Fareed J, Toner G, Green MD, Basser RL. Rosenthal MA, et al. Among authors: rischin d. Ann Oncol. 2002 May;13(5):770-6. doi: 10.1093/annonc/mdf117. Ann Oncol. 2002. PMID: 12075747 Free article. Clinical Trial.

6

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, Kaye SB, Gianni L, Harris A, Bjork T, Averbuch SD, Feyereislova A, Swaisland H, Rojo F, Albanell J. Baselga J, et al. Among authors: rischin d. J Clin Oncol. 2002 Nov 1;20(21):4292-302. doi: 10.1200/JCO.2002.03.100. J Clin Oncol. 2002. PMID: 12409327 Clinical Trial.

7

Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics.

Rischin D, Ackland SP, Smith J, Garg MB, Clarke S, Millward MJ, Toner GC, Zalcberg J. Rischin D, et al. Ann Oncol. 2002 Nov;13(11):1810-8. doi: 10.1093/annonc/mdf305. Ann Oncol. 2002. PMID: 12419756 Free article. Clinical Trial.

8

Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients.

Millward MJ, Boyer MJ, Lehnert M, Clarke S, Rischin D, Goh BC, Wong J, McNeil E, Bishop JF. Millward MJ, et al. Among authors: rischin d. Ann Oncol. 2003 Mar;14(3):449-54. doi: 10.1093/annonc/mdg118. Ann Oncol. 2003. PMID: 12598352 Free article. Clinical Trial.

9

Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer.

Millward MJ, Zalcberg J, Bishop JF, Webster LK, Zimet A, Rischin D, Toner GC, Laird J, Cosolo W, Urch M, Bruno R, Loret C, James R, Blanc C. Millward MJ, et al. Among authors: rischin d. J Clin Oncol. 1997 Feb;15(2):750-8. doi: 10.1200/JCO.1997.15.2.750. J Clin Oncol. 1997. PMID: 9053501 Clinical Trial.

10

Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer.

Rischin D, Peters L, Hicks R, Hughes P, Fisher R, Hart R, Sexton M, D'Costa I, von Roemeling R. Rischin D, et al. Among authors: d costa i. J Clin Oncol. 2001 Jan 15;19(2):535-42. doi: 10.1200/JCO.2001.19.2.535. J Clin Oncol. 2001. PMID: 11208848 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

306 results

Search Page

Filters